Researchers published in The Lancet present full 2023 MASAI trial results showing AI-supported mammography in Sweden's national screening programme led to more early cancer detections and fewer interval cancers. Between April 2021 and December 2022, 105,900+ women were randomized; AI reduced interval cancer diagnoses by 12% and raised screening detection to 81% while false-positive rates remained similar. AI also cut radiologist workload by 44%.
Key Points
- 1Demonstrates 12% fewer interval cancers over two years with AI-supported screening
- 2Increases screen-detection rate to 81%, a 9% absolute rise versus standard double reading
- 3Reduces radiologist workload by 44%, enabling resource reallocation and faster throughput
Scoring Rationale
High-quality Lancet randomized trial shows meaningful clinical benefits, though results stem mainly from one national programme and short-term follow-up.
Sources
Public references used for this report.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Ad Tech problems
